Business Wire

XPUBLISHER-GMBH

15.12.2022 15:08:33 CET | Business Wire | Press release

Share
Xpublisher Software-as-a-Service Takes Publishing to a New Level

For the first time, Xpublisher GmbH’s editing system will feature a cloud-based SaaS architecture. “This makes our multichannel publishing system instantly accessible and ready to use from anywhere,” notes Xpublisher CEO Matthias Kraus. “Thanks to a broad spectrum of customization options, users can tailor the software to suit their unique requirements and preferences.” The user interface also features barrier-free accessibility and an updated design.

Multichannel publishing with customizable scalability

Expanding and enhancing business logic is possible at any time with no need for complex custom programming, as well as increasing the number of users, the amount of storage space, and the scope of services. Updates and enhancements go live automatically. The graphical BPMN editor lets users design their own workflows that will help to digitalize even the most complex work processes and boost collaboration. With a personalized worklist, everyone has an instant overview of all pending tasks, together with the status of the overall process.

Digital asset management

Integrated, high-performance digital asset management adds yet a further new innovation. It keeps all the content organized in one place, and by adding metadata, it gives users drag-and-drop control over their data. They can edit these assets straight from their existing desktop applications, including Adobe Photoshop and InDesign as well as Microsoft PowerPoint. Xpublisher Digital Asset Management can be licensed either as part of Xpublisher Multichannel Publishing or separately, offering businesses maximum flexibility.

Publish on any channel

From content authoring and management to final publication, the new Xpublisher guides users throughout the entire content production process. Xpublisher specializes in output for digital channels as well as fully or partially automated processes for producing magazines, books, technical documentation, legal documents, and financial reports.

Xpublisher on Fabasoft PROCECO

The Xpublisher Multichannel Publishing system is part of Fabasoft’s PROCECO business process ecosystem. As a curated operating environment, it brings together select, mutually compatible, high-quality digital solutions for document-intensive business processes. The powerful Fabasoft Cloud serves as the technological base. Fabasoft Group's software products and cloud services have received numerous international certifications and awards for reliability, data and data center security, and accessibility.

About Xpublisher GmbH

Xpublisher is a leading provider in the multichannel publishing space, delivering intuitive solutions for creating, managing, and automating magazine, book, and documentation publishing with Xeditor and Xpublisher. Xpublisher was founded in 2009 and is based in Munich, Germany. The company operates a US subsidiary and has been part of the Fabasoft Group since 2019. Numerous leading international companies and organizations in the publishing, aerospace, technology, education, and public administration sectors together with a host of other industries have already placed their trust in Xpublisher’s products.

For more information, visit www.xpublisher.com or follow us on LinkedIn and Twitter @Xpublisher.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005595/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye